Published in Medical Letter on the CDC and FDA, August 12th, 2007
Under the FDA Modernization Act of 1997, the Fast Track designation program is intended to facilitate the development and expedite review of drugs developed for the treatment of serious or life-threatening conditions and that demonstrate the potential to address an unmet medical need for such a condition.
As previously announced, Neurochem requested a meeting with the FDA, which is now scheduled for August...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA